Your browser doesn't support javascript.
loading
Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis.
Sise, Meghan E; Wang, Qiyu; Seethapathy, Harish; Moreno, Daiana; Harden, Destiny; Smith, R Neal; Rosales, Ivy A; Colvin, Robert B; Chute, Sarah; Cornell, Lynn D; Herrmann, Sandra M; Fadden, Riley; Sullivan, Ryan J; Yang, Nancy J; Barmettler, Sara; Wells, Sophia; Gupta, Shruti; Villani, Alexandra-Chloe; Reynolds, Kerry L; Farmer, Jocelyn.
Affiliation
  • Sise ME; Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA msise@partners.org.
  • Wang Q; Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Seethapathy H; Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Moreno D; Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Harden D; Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Smith RN; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Rosales IA; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Colvin RB; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Chute S; Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Cornell LD; Department of Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Herrmann SM; Department of Nephrology & Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
  • Fadden R; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Sullivan RJ; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Yang NJ; Department of Medicine, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Barmettler S; Department of Medicine, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Wells S; Department of Medicine, Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Gupta S; Department of Medicine, Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Villani AC; Department of Oncology, Adult Survivorship Program, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Reynolds KL; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Farmer J; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
J Immunother Cancer ; 11(1)2023 01.
Article in En | MEDLINE | ID: mdl-36657813
BACKGROUND: Non-invasive biomarkers of immune checkpoint inhibitor-associated acute tubulointerstitial nephritis (ICI-nephritis) are urgently needed. Because ICIs block immune checkpoint pathways that include cytotoxic T lymphocyte antigen 4 (CTLA4), we hypothesized that biomarkers of immune dysregulationpreviously defined in patients with congenital CTLA4 deficiency, including elevated soluble interleukin-2 receptor alpha (sIL-2R) and flow cytometric cell-based markers of B and T cell dysregulation in peripheral blood may aid the diagnosis of ICI-nephritis. METHODS: A retrospective cohort of patients diagnosed with ICI-nephritis was compared with three prospectively enrolled control cohorts: ICI-treated controls without immune-related adverse events, patients not on ICIs with hemodynamic acute kidney injury (hemodynamic AKI), and patients not on ICIs with biopsy proven acute interstitial nephritis from other causes (non-ICI-nephritis). sIL-2R level and flow cytometric parameters were compared between groups using Wilcoxon rank sum test or Kruskal-Wallis test. Receiver operating characteristic curves were generated to define the accuracy of sIL-2R and flow cytometric biomarkers in diagnosing ICI-nephritis. The downstream impact of T cell activation in the affected kidney was investigated using archived biopsy samples to evaluate the gene expression of IL2RA, IL-2 signaling, and T cell receptor signaling in patients with ICI-nephritis compared with other causes of drug-induced nephritis, acute tubular injury, and histologically normal controls. RESULTS: sIL-2R level in peripheral blood was significantly higher in patients with ICI-nephritis (N=24) (median 2.5-fold upper limit of normal (ULN), IQR 1.9-3.3), compared with ICI-treated controls (N=10) (median 0.8-fold ULN, IQR 0.5-0.9, p<0.001) and hemodynamic AKI controls (N=6) (median 0.9-fold-ULN, IQR 0.7-1.1, p=0.008). A sIL-2R cut-off point of 1.75-fold ULN was highly diagnostic of ICI-nephritis (area under the curve >96%) when compared with either ICI-treated or hemodynamic AKI controls. By peripheral blood flow cytometry analysis, lower absolute CD8+T cells, CD45RA+CD8+ T cells, memory CD27+B cells, and expansion of plasmablasts were prominent features of ICI-nephritis compared with ICI-treated controls. Gene expressions for IL2RA, IL-2 signaling, and T cell receptor signaling in the kidney tissue with ICI-nephritis were significantly higher compared with controls. CONCLUSION: Elevated sIL-2R level and flow cytometric markers of both B and T cell dysregulation may aid the diagnosis of ICI-nephritis.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Acute Kidney Injury / Immune Checkpoint Inhibitors / Nephritis, Interstitial Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Immunother Cancer Year: 2023 Document type: Article Affiliation country: United States Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Acute Kidney Injury / Immune Checkpoint Inhibitors / Nephritis, Interstitial Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Immunother Cancer Year: 2023 Document type: Article Affiliation country: United States Country of publication: United kingdom